Voyager Therapeutics (VYGR)
(Real Time Quote from BATS)
$3.10 USD
+0.14 (4.73%)
Updated Aug 4, 2025 11:48 AM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VYGR 3.10 +0.14(4.73%)
Will VYGR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Other News for VYGR
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing ...
Voyager Therapeutics (VYGR) Enhances Alzheimer's Program with New Initiative | VYGR Stock News
Voyager Therapeutics continues expansion of its AD franchise
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR ...
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)